BMCC-2022-PL02

Quantity and Quality Controlled Bioprocess of Chimeric Antigen Receptor (CAR)-T Cells

BMCC

Quantity and Quality Controlled Bioprocess of Chimeric Antigen Receptor (CAR)-T Cells

未定中標題
BMCC Targeted indication

Cancer diseases

BMCC Status

Non-clinical studies

BMCC Key features
  • High cell expansion fold: Average 93-188 folds in 6 day-expansion.
  • Major cellular immunity populations: Th1 and CTL were major subsets
  • Higher cytotoxicity activity and cytokine production: Increase 5-10% of target cell killing and 5-30 ng/mL of IFN-γ production
BMCC Market
  • In this process, it could reduce the requirement of initial T cell number to 1 to 10 million T cells to perform basic research or clinical treatment.
  • Shortening operation time within 10 days and culturing cells at up to4 million cells/mL could lead to the reduction of occupancy of equipment and consumption of materials.
  • Control of cell subsets shows the potential of the persistence and potency of CAR-T cells.

MODE OF ACTION

In our process, it could reduce the requirement of initial T cell number to 1 to 10 million T cells to perform basic research or clinical treatment. Shortening operation time within 10 days and culturing cells at up to4 million cells/mL could lead to the reduction of occupancy of equipment and consumption of materials.

EXPERIMENTAL RESULTS

in vitro efficacy
  • CAR-T cells expanded to average 188 folds of initial cell number in a 6-day culture in vitro.
  • The T cell subsets in this serum-free culture condition were majorly early differentiated Th1 and CTLs.
  • The T cell cytotoxicity and cytokine production responding to target cells in DCB’s condition were superior to those in benchmark condition.

in vivo efficacy

  NA

INTELLECTUAL PROPERTY

NA

SELECTED PUBLICATIONS

NA

BUSINESS OPPORTUNITY

License and/or Collaboration

CONTACT

service@biip-dcc.org

*欲下載完整檔案請 登入/ 會員註冊